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 Mice infected with T. cruzi control acute
parasitemia but develop chronic chagasic
cardiomyopathy.
 Treatment with SIL (a phosphodiesterase
inhibitor) during a therapeutic window of
indeterminate phase provided powerful
cardioprotective effects against chronic
development of cardiomyopathy and LV
dysfunction.
 SIL normalized the cGMP-dependent
protein kinase activity and mitochondrial
oxidative metabolism, and established
the oxidant/antioxidant balance in
chagasic myocardium.
 SIL prevented the oxidative/inﬂammatory
adducts that precipitate cardiomyocytes
death and cardiac remodeling in CCM.Galveston, Texas; bDepartment of
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ABBR EV I A T I ON S
AND ACRONYMS
ANOVA = analysis of varia
CCM = chagasic
cardiomyopathy
cGMP = cyclic guanosine
monophosphate
Ct = threshold cycle
DCF =
dichlorodihydroﬂuorescein
DHE = dihydroethidium
DMSO = dimethyl sulfoxid
EF = ejection fraction
ER = endoplasmic reticulum
GC = guanylyl cyclase
HRP = horseradish peroxid
K-W = Kruskal-Wallis
LDH = lactate dehydrogen
LPO = lipid hydroperoxide
LV = left ventricle/ventricu
mtDNA = mitochondrial D
NO = nitric oxide
OD = optical density
PDE = phosphodiesterase
pi = post-infection
PKG = cGMP-dependent
protein kinase
QR1 = quartile 1
RCR = respiratory control
ROS = reactive oxygen spe
SIL = sildenaﬁl
SV = stroke volume
Tc = Trypanosoma cruzi
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cieMolecular mechanisms of Trypanosoma cruzi (Tc)-induced Chagasic cardiomyopathy (CCM) are not well understood. The
NO-cGMP-PKG1a pathwaymaintains cardiac homeostasis and inotropy andmay be disturbed due to phosphodiesterase (PDE5)-
mediatedcGMPcatabolism inCCM.Totest this,C57BL/6micewere infectedwithT. cruzi, andafter thecontrolofacuteparasitemia
(w45dayspost-infection), given sildenaﬁl (SIL) (1mg/kg) treatment for 3weeks that ended longbefore the chronicdiseasephase
(w150 days post-infection). The PDE5 was increased and cGMP/PKG activity was decreased in chagasic myocardium. Transtho-
racic echocardiography revealed left ventricular (LV) systolic function, that is, stroke volume, cardiac output, andejection fraction,
wassigniﬁcantlydecreased inchagasicmice.SIL treatment resulted innormal levelsofPDE5andcGMP/PKGactivityandpreserved
the LV function. The cardioprotective effects of SIL were provided through inhibition of cardiac collagenosis and chronic inﬂam-
mation that otherwise were pronounced in CCM. Further, SIL treatment restored the mitochondrial DNA–encoded gene expres-
sion, complex I–dependent (but not complex II–dependent) ADP-coupled respiration, andoxidant/antioxidant balance in chagasic
myocardium. In vitro studies in cardiomyocytes veriﬁed that SIL conserved the redox metabolic state and cellular health via
maintaining the antioxidant status that otherwisewas compromised in response toT. cruzi infection.Weconclude that SIL therapy
wasuseful in controlling theLVdysfunction andchronic pathology inCCM. (JAmColl Cardiol Basic Trans Science2016;1:235–50)
© 2016 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).o
sC hagasic cardiomyopathy (CCM) is anillness initiated by Trypanosomacruzi infection. In Latin America,
w13 million people are infected and 120
million are believed to be at risk of infection
via vectorial, congenital, and other modes of
transmission (1). Vectorial transmission oc-
curs in the United States (2), and >300,000
infected individuals living in the United
States can potentially transfer infection
through blood and organ donation (3–5).
Approximately, 30% to 40% of the infected
individuals manifest prolonged micro and
macro cardiac injuries that cause hypertro-
phy and increased stiffness of the left ventric-
ular (LV) walls, and ultimately lead to a
clinical presentation of ventricle arrhythmia,
thromboembolism, and heart failure (6). Due
to a lack of accurate therapies (7), CCM causes
approximately $8 billion/year in costs in
health care and loss of productivity (8).
Molecular mechanisms of T. cruzi (Tc)-
induced CCM are not well understood. Early
upon infection, T. cruzi is shown to up-
regulate in human cardiac myocytes the
expression of several transcription factors
and cytokines/chemokines implicated in the
development of ﬁbrogenic response (9).
Chronic progression of CCM is associated
with persistent increase in circulatory and
myocardial inﬂammatory and oxidative
stress in human patients and experimental
models (reviewed in [10]). Although inﬂam-
matory stress is believed to be present inresponse to T. cruzi infection, we showed that mito-
chondrial inefﬁciency of respiratory chain was the
major source of reactive oxygen species (ROS) in the
heart (11). Treatment of chagasic mice with a ROS
scavenger (12) and mice genetically enhanced in their
capacity to scavenge mitochondrial ROS (13) were
better equipped in handling the oxidative and in-
ﬂammatory stress, thus suggesting that ROS may
signal chronic inﬂammation during CCM.
In the heart, nitric oxide (NO) and atrial natriuretic
peptide signal the activation of guanylyl cyclase (GC)
that produces cyclic guanosine monophosphate
(cGMP) (14). The cGMP binding activates cGMP-
dependent protein kinase (PKG). PKG phosphory-
lates serine and threonine residues on many cellular
proteins and mediates the downstream effects in
maintaining the force of contraction of cardiac myo-
cytes (15) through regulating cytosolic free Ca2þ level
and sensitivity of muscle ﬁbers to Ca2þ (16). Others
have implied that cGMP/PKG regulate the activities of
phosphodiesterases (PDEs) that hydrolyze cyclic nu-
cleotides (17). Of the 4 PDEs that are expressed in the
heart and, in a feedback mechanism, that hydrolyze
cyclic nucleotides, PDE5 is the only known cardiac
phosphodiesterase that selectively hydrolyzes cGMP
and negatively regulates cardiac inotropy (18). An
observation of PDE5 subcellular localization to myo-
cyte z-bands (19) implies that it may exert its effects
on cGMP/PKG signaling in a spatiotemporal manner
and determine the functional outcomes in stressed
heart. The NO-cGMP-PKG signaling may also occur in
mitochondria and play a role in ischemic pre-
conditioning and antioxidant cardioprotection (20),
though the exact mechanism remains to be identiﬁed.
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237In this study, we aimed to determine whether
treatment with PDE5 inhibitors would be beneﬁcial in
preserving cardiac hemodynamics in CCM. We also
determined themolecular mechanism of cGMP/PKG in
preventing pathological outcomes in CCM. We discuss
the therapeutic role of PDE5 inhibitors in arresting the
myocardial inﬂammation and mitochondrial oxida-
tive stress that are hallmarks of chronic CCM.
MATERIALS AND METHODS
ETHICS STATEMENT. All animal experiments were
performed according to the National Institutes of
Health Guide for Care and Use of Experimental Ani-
mals, and was approved by the Institutional Animal
Care and Use Committee at the University of Texas
Medical Branch, Galveston (protocol number: 805029).
MICE, PARASITES, AND CELL CULTURE. All experi-
ments were conducted in C57BL/6 (wild-type, female)
mice, and all mice were purchased from Harlan Lab-
oratories (Indianapolis, Indiana). T. cruzi trypomas-
tigotes (SylvioX10/4) were propagated by in vitro
passage in C2C12 cells. Mice were randomly assigned
to different groups. Mice (6-weeks-old) were infected
with T. cruzi (10,000 trypomastigotes/mouse, intra-
peritoneal), and survival from infection was moni-
tored daily. Sildenaﬁl (SIL) solution (25 mg/100 ml of
0.5% dimethyl sulfoxide [DMSO]) was freshly made,
and treatment with SIL (1 mg/kg, intraperitoneal) was
initiated at day 45 post-infection (pi) when mice had
controlled acute parasitemia, and was conducted
twice a week for 3 weeks. The selected low concen-
tration of SIL was shown to be safe while providing
cardiac beneﬁts in previous studies (21). Mice were
sacriﬁced at w150 days pi corresponding to the
chronic disease phase. Sera/plasma and tissue sam-
ples were stored at 4

C and 80oC, respectively.
PKG ACTIVITY. A CycLex cGK (PKG) ELISA Assay Kit
(MBL International Corp, Woburn, Massachusetts)
was used to measure the PKG activity. Brieﬂy, tissue
homogenates (10-mg protein/10 ml) were added to
96-well plates pre-coated with histone H1 peptide
containing threonine residues, and sequentially
incubated for 30 min in the presence of cGMP and
ATP, and then for 60 min with horseradish peroxidase
(HRP)-conjugated anti–phospho-G-kinase substrate
threonine 68/119 monoclonal antibody. Plates were
washed, and the HRP-catalyzed conversion of chro-
mogenic TMB substrate to a blue color was recorded
at 450/540 nm (standard curve 1- to 10-U recombinant
cGK [PKG] protein).
ECHOCARDIOGRAPHY. Mice were sedated with
inhalant anesthesia (1.5% isoﬂurane/100% O2), placed
supine on an electrical heating pad at 37C, and heartrate and respiratory physiology were continuously
monitored by electrocardiography. After shaving the
chest, warmed ultrasound gel was applied, and
transthoracic echocardiography was performed using
the Vevo 2100 ultrasound system (VisualSonics, Tor-
onto, Canada) equipped with a high-frequency linear
array transducer (MS400, 18 to 38 MHz) (22). Heart
was imaged in B-mode and M-mode to examine the
parameters of the left ventricle (LV) in diastole and
systole. All measurements were obtained in triplicate,
and data were analyzed using the Vevo 2100 standard
measurement package.
HISTOLOGY. Tissue sections were ﬁxed in 10% buff-
ered formalin for 24 h, dehydrated in absolute
ethanol, cleared in xylene, and embedded in parafﬁn.
Five-micron tissue sections were subjected to staining
with hematoxylin and eosin or Mason’s Trichrome at
the Research Histopathology Core at the University of
Texas Medical Branch, and evaluated by light micro-
scopy using an Olympus BX-15 microscope (Center
Valley, Pennsylvania) equipped with a digital camera
and Simple PCI software (v.6.0; Compix, Sewickley,
Pennsylvania). Myocarditis (presence of inﬂammatory
cells) in hematoxylin and eosin–stained tissue sec-
tions was scored as 0 (absent), 1 (focal/mild, #1 foci), 2
(moderate, $2 inﬂammatory foci), 3 (extensive, coa-
lescing of inﬂammatory foci or disseminated in-
ﬂammation), and 4 (diffused inﬂammation, tissue
necrosis, interstitial edema, and loss of integrity). In-
ﬂammatory inﬁltrates were characterized as diffused
or focal depending upon how closely the inﬂamma-
tory cells were associated (23). Fibrosis was assessed
by measuring the collagen area as a percentage of the
total myocardial area, and categorized as 0 (<1%), 1
(1% to 5%), 2 (5% to 10%), 3 (10% to 15%), and 4 (>15%)
on the basis of percent ﬁbrotic area (23).
GENE EXPRESSION ANALYSIS. Heart tissue-sections
(10 mg) were homogenized in 100 ml of TRIzol
reagent (Invitrogen, Carlsbad, California), and total
RNA was extracted and precipitated by the
chloroform/isopropanol/ethanol method. DNA that
might be contaminating the RNA preparation was
removed by RNase-Free DNase I (New England Bio-
labs, Beverly, Massachusetts) treatment. Total RNA
was analyzed by using a DU 800 UV/Visible Spectro-
photometer (Beckman Coulter, Pasadena, California)
and absorbance read at 260 nm and 280 nm to assess
the quality (optical density [OD]260/OD280 ratio $2.0)
and quantity (OD260 of 1 ¼ 40 mg/ml RNA). An aliquot
of total RNA was run on a 1.5% denaturing agarose gel
to assess the integrity (28S/18S, 2:1 ratio). Total RNA
(2 mg) was reverse transcribed with Oligo(dT)20 primer
using SuperScript III Reverse Transcriptase (Invi-
trogen). The cDNA was used as a template in a
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238real-time quantitative polymerase chain reaction on
an iCycler Thermal Cycler with SYBR-Green Supermix
(Bio-Rad, Hercules, California) and gene-speciﬁc oli-
gonucleotides (Table 1). The threshold cycle (Ct)
values for target mRNAs were normalized to GAPDH
mRNA, and the relative expression level of each
target gene was calculated as 2DDCt, where DCt rep-
resents the Ct (sample)  Ct (control). The fold change
represents (the target 2DDCt / the control 2DDCt) (12).
WESTERN BLOTTING. Freshly harvested heart
tissues were minced in ice-cold HMSB medium
(10 mmol/l HEPES [pH 7.4], 225 mmol/l mannitol,
75 mmol/l sucrose, and 0.2% fatty acid-free bovine
serum albumin; tissue/buffer ratio, 1:20), homoge-
nized in a Dounce homogenizer, and centrifuged at
600 g to pellet the debris. Heart homogenates (20 mg
of protein) were electrophoresed on a 10%
Mini-Protein TGX gel using a Mini-PROTEAN elec-
trophoresis chamber (Bio-Rad), and proteins were
transferred to a polyvinylidene diﬂuoride membrane
using a semidry transfer system (Bio-Rad). Mem-
branes were blocked with 5% nonfat dry milk in 50
mmol/l Tris-HCl (pH 7.5)/150 mmol/l NaCl (TBS),
washed with TBS-0.1% Tween 20, and incubated
overnight at 4C with antibodies against PDE5 (cat#
ab14672; Abcam, San Francisco California) and
GAPDH (cat#3683; Cell Signaling Technology, Dan-
vers, Massachusetts). Membranes were incubated
with HRP-conjugated secondary antibody (1:5,000
dilution, cat# 4041-05; Southern Biotech, Birming-
ham Alabama), and signal was captured by using an
ImageQuant LAS4000 system (GE Healthcare, Pitts-
burgh, Massachusetts). Densitometry analysis of
protein bands of interest was performed using a
Fluorchem HD2 Imaging System (Alpha-Innotech, San
Leandro, California), and normalized against GAPDH.TABLE 1 Oligonucleotides Used in the Study
Gene 50-Forward-30 50
ATP6 CCTTCCACAAGGAACTCCA GGTAGCTGT
Collagen I GAGCGGAGAGTACTGGATCG GCTTCTTTT
Collagen III GCACAGCAGTCCAACGTAGA TCTCCAAAT
COXIII CCTTCGACCTGACAGAAGGA GATGCTCGG
Cyt B ATTCCTTCATGTCGGACGAG ACTGAGAAG
GAPDH AACTTTGGCATTGTGGAAGG ACACATTGG
GSK3b CAGTGGTGTGGATCAGTTGG ATGTGCACA
MnSOD CACATTAACGCGCAGATCATG CCAGAGCCT
ND1 CTGGCTACTGCGTACATCCA TCTCCAAAC
ND4 AGGACTTCCACATGGAGATTGGCA AGACTGCAT
PDE5 GGAAGCGTGGCTGGATGATCAC AAGAGCAGG
SERCA2 CTGTGGAGACCCTTGGTTGT CAGAGCACA
bp ¼ base pairs.LACTATE DEHYDROGENASE. Lactate dehydroge-
nase (LDH) activity in tissue homogenates and plasma
was measured by using a 2-step kit (Cayman Chem-
icals, Ann Arbor, Michigan). Brieﬂy, LDH-catalyzed
reduction of NADþ to NADH by oxidation of lactate
to pyruvate was coupled with reduction of tetrazo-
lium salt to blue formazan crystals, and absorbance
was monitored at 490 to 520 nm by spectrophotom-
etry (standard curve 1 to 1,000 mU of LDH).
TISSUE PARASITE BURDEN. Heart tissues were har-
vested from normal, Tc-infected, and Tc-infected/
SIL-treated mice as described earlier in the text. A
batch of Tc-infected mice were injected with DMSO
(0.5%, 100 ml per mouse, vehicle for dissolving SIL)
and used to evaluate the potential effect of DMSO on
parasite burden. Tissue sections (10 mg) were sub-
jected to proteinase-K lysis, and total DNA was
extracted by the phenol/chloroform extraction/
ethanol precipitation method. Total DNA was treated
with RNase A (DNase and protease-free, cat#EN0531,
Thermo Fisher Scientiﬁc, Waltham, Massachusetts)
and puriﬁed by using DNeasy Mini Spin Columns
(Qiagen, Hilden, Germany). Total DNA absorbance
was recorded at 260 and 280 nm by using a DU 800
UV/Visible Spectrophotometer, and DNA concentra-
tion ([OD260  OD320]  50 mg/ml) and purity
(OD260/OD280 ratio of 1.7 to 2.0) recorded. Total DNA
(100 ng) was submitted to a real-time polymerase
chain reaction on an iCycler thermal cycler with SYBR
Green Supermix (Bio-Rad) and Tc18SrDNA-speciﬁc
primers (forward: 50-TAGTCATATGCTTGTTTC-30,
reverse: 50-GCAACAGCATTAATATACGC-30), and fold
change was calculated as described earlier in the text.
MITOCHONDRIAL RESPIRATION. Freshly harvested
tissue sections (30 mg) were minced in 500 ml of
ice-cold HMSB medium (10 mmol/l HEPES pH 7.4,-Reverse-30 Amplicon Size (bp) Accession #
TGGTGGGCTAAA 195 NC_005089
CCTTGGGGTTC 158 BC050014
GGGATCTCTGG 185 BC058724
ATCCATAGGAA 238 DQ106413.1
CCCCCTCAAAT 228 GI325511952
GGGTAGGAACA 223 NM_008084.2
AGCTTCCAGTG 232 NM_019827.6
CGTGGTACTTCTC 79 NM_013671.3
CCTTTGACACA 142 NM_004541.3
GTTATTGCGAGCAGG 162 NM_002495.2
ACTCGGTATGGGC 152 NM_153422.2
GATGGTGGCTA 145 NR_027838.1
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239225 mmol/l mannitol, 75 mmol/l sucrose, and 0.2%
fatty acid-free bovine serum albumin) containing 200
U/ml collagenase and homogenized on ice using a
Dounce homogenizer. Collagenolysis was stopped
with addition of 1 mmol/l EGTA, and tissue homoge-
nates were centrifuged at 4C for 10 min each at 600 g
(to remove debris) and 8,000 g to pellet the mito-
chondrial fraction (24).
Mitochondrial respiration was measured by using a
Mitocell S200A Respirometry System (Strathkelvin,
Motherwell, United Kingdom). Brieﬂy, a micro-
cathode oxygen electrode was calibrated, and freshly
isolated mitochondria (200 mg) suspended in 0.5 ml of
MSP buffer (225 mmol/l mannitol, 75 mmol/l sucrose,
20 mmol/l KH2PO4/K2HPO4 [pH 7.6]) were added to
the Mitocell. After recording the basal O2 consump-
tion, 230 mmol/l ADP was added, allowing the ATP
synthase to function and complex I (10 mmol/l
pyruvate/10 mmol/l glutamate/2.5 mmol/l malate) or
complex II (5 mmol/l succinate/6.25 mmol/l rotenone)
coupled state 3 respiration (indicates ATP production
rate) was recorded (24).
OXIDATIVE STRESS. The in situ ROS level was
measured in cryostat sections. Tissue sections (10 mm)
were equilibrated in Kreb’s buffer and incubated in the
dark for 30 min with 5 mmol/l MitoSOX Red (Invi-
trogen). MitoSOX Red oxidation by mitochondrial
ROS, resulting in red ﬂuorescence (Ex518nm/Em605nm),
was detected on an Olympus BX-15 microscope and
images were captured by using a mounted digital
camera.
We used an LPO Assay Kit (Cayman Chemicals) to
measure the lipid peroxides. Brieﬂy, lipid hydroper-
oxide (LPO) in tissue homogenates or plasma samples
were extracted into chloroform, and added to 50 ml of
4.5 mmol/l FeSO4 in 0.2 mol/l HCl / 3% NH4SCN in
methanol (1:1, v/v). The redox reaction with ferrous
ions was stopped after 5 min, and absorbance was
monitored at 500 nm (standard curve 0 to 500 mmol/l
13-hydroperoxy octadecadienoic acid).
The protein carbonyls in tissue homogenates were
measured by a colorimetric protein carbonyl assay
(Cayman Chemicals), according to the instructions
provided by the manufacturer.
ROS release by Tc-infected cells (SIL) was
measured by an Amplex red assay. Brieﬂy, samples
(10 mg of protein) were added in triplicate to 96-well,
black, ﬂat-bottom plates. The reaction was initiated
with addition of 50 ml each of 100 mmol/l Amplex red
(Invitrogen) and 0.3 U/ml HRP. The HRP-catalyzed
Amplex red oxidation by H2O2, resulting in ﬂuores-
cent resoruﬁn formation, was monitored at Ex563 nm/
Em587 nm (standard curve 50 nmol/l  5 mol/l H2O2).ANTIOXIDANT LEVELS. MnSOD activity in tissue
homogenates was measured using a Superoxide Dis-
mutase Assay kit (Cayman Chemicals). The assay uses
a tetrazolium salt for detection of superoxide radicals
generated by xanthine oxidase and hypoxanthine.
One unit of SOD was deﬁned as the amount of MnSOD
needed for 50% dismutation of the superoxide radical
(standard curve 0.005 to 0.05 U/ml recombinant
CuZnSOD).
Total antioxidant capacity was assessed using lag
time by antioxidants against the myoglobin-induced
oxidation of 2,2’-azino-di(3-ethylbenzthiazoline-6-
sulfonic acid (ABTS) with H2O2. Brieﬂy, 20 ml of
plasma samples (diluted 1:20, v/v) were added in
triplicate to 96-well plates, and mixed with 90 ml of
10 mmol/l PBS (pH 7.2), 50 ml of myoglobin solution,
and 20 ml of 3 mmol/l ABTS. Reaction was initiated
with H2O2 (20 ml), and change in color was monitored
at 600 nm (standard curve 2 to 25 mmol/l trolox).
FLUORESCENCE MICROSCOPY, NADD/NADH RATIO, CELL
VIABILITY, AND TRANSIENT TRANSFECTION. Cultured
cardiac myocytes (105 cells/well in 24-well plates)
were infected with T. cruzi (cell/parasite ratio, 1:5)
and incubated in presence or absence of 100 nmol/l
SIL for 24 h. Cells were loaded for 30 min with 50 ml of
cell permeable dyes (Molecular Probes, Eugene, Ore-
gon), washed, and then the change in intracellular
ﬂuorescence was visualized and recorded by using an
ECLIPSE Ti inverted microscope equipped with a
digital camera (magniﬁcation 40). The 2’,7’-bis-(2-
carboxyethyl)-5-(and-6)-carboxyﬂuorescein (BCECF
acid, 2 to 10 mmol/l, Ex490nm/Em535nm) was used as
a dual-excitation ratiometric indicator of changes
in intracellular pH. Fluo-4 AM (1 mmol/l,
Ex485nm/Em520nm) was used to measure the changes
in intracellular Ca2þ concentrations in response to Tc
infection. Cells were also loaded with 100 mmol/l
dihydroethidium (DHE) or 10 mmol/l CM-H2DCF-DA,
and the formation of ﬂuorescent ethidium
(Ex498nm/Em598nm, detects intracellular O2) and
dichlorodihydroﬂuorescein (DCF) (Ex498nm/Em598nm,
detects intracellular H2O2), respectively, were moni-
tored by ﬂuorescence microscopy.
To evaluate the cell viability, HeLa cells (1  104/
well) were seeded in 96-well plates, and infected and
incubated with or without SIL for 24 h, as described
earlier in the text. Cells were washed, replenished
with fresh medium (100 ml), loaded with 20 ml of MTT
solution (5 mg/ml of 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide), and incubated for
4 h. The MTT is metabolized by NAD(P)H-dependent
cellular oxidoreductases, resulting in the formation
of insoluble blue formazan crystals. Formazan crys-
tals were dissolved in 100 ml of DMSO, and the
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240absorbance was recorded at 490 nm with a reference
wavelength of 620 nm.
The NADþ/NADH ratio was measured by using a
Fluorometric Assay Kit (Abcam, Cambridge, United
Kingdom) according to instructions provided by the
manufacturer. Brieﬂy, tissue homogenates were
deproteinized with 1 mol/l perchloric acid, neutral-
ized with equal volume of ice-cold 2 mol/l KOH, and
centrifuged to obtain clear supernatant. Samples
(50 ml/well) were added in triplicate to a 96-well plate,
and NADH formation in the presence of 100 ml of NAD
cycling mix and 10 ml of NADH developer was recor-
ded. A standard curve was prepared using 1 to 100
pmol/l NADH, and NADþ/NADH ratio in samples
calculated as (NADtotal  NADH) / NADH.
The eukaryotic plasmids pBI.EGFP and pBI.EGFP-
MnSOD (express full-length MnSOD, from Addgene,
Cambridge, Massachusetts) (25) were transformed
into Escherichia coli DH5 competent cells, grown in
L-broth containing appropriate antibiotics (100
mg/ml), and puriﬁed using the Plasmid DNA Maxi
Prep kit (Qiagen). Cultured cardiac myocytes were
seeded (104 cells/well) in Lab-Tek II 8-well chamber
slides (Nunc, Rochester, New York) and incubated
overnight at 37C, 5% CO2 in antibiotic-free Opti-
MEM medium. Cells were transfected with pBI.EGFP
or pBI.EGFP-MnSOD (100 ng) by using Lipofect-
amine 2000 reagent (Invitrogen) following the in-
structions provided by the manufacturer; and 6 h
after transfection, cells were visualized by optical
and ﬂuorescence microscopy. The number of total
and GFPþ cells were counted per microscopic ﬁeld
(10 ﬁelds per slide), and transfection efﬁciency was
evaluated ([GFPþ  100] / total cells). After 6 h of
incubation, cells were washed, replenished with
complete medium for 3 to 5 h, infected with T. cruzi
(cell/parasite ratio, 1:5), and incubated with or
without 100 nmol/l SIL for 24 h. The relative EGFP-
conjugated MnSOD expression was detected by
ﬂuorescence microscopy.
DATA ANALYSIS. Mice were randomly assigned to 3
groups (no treatment, T. cruzi infection, or T. cruzi
infection followed by SIL treatment, n $ 6 mice per
group per experiment). All experiments were con-
ducted in 2 sets of mice per group, with triplicate
observations per sample. Data were expressed as
mean  SEM. All data were analyzed using GraphPad
Prism 5 software (version 5.04) (GraphPad Software,
La Jolla, California). Data (linear range or log10 trans-
formed) were analyzed by the Kolmogorov-Smirnov
test to determine whether the data are normally
distributed. Normally distributed data were analyzed
by 1-way analysis of variance (ANOVA) with post-hoc
Tukey test. If data were not normally distributed,then Kruskal-Wallis (K-W) with Dunn tests were used,
and median  quartile 1 (QR1) values were also
calculated. Signiﬁcance is presented by *Tc-infected
versus normal or #Tc-infected versus Tc/SIL-treated
(*,#p < 0.05, **,##p < 0.01, ***,###p < 0.001).
RESULTS
We used a well-established experimental model (26)
to assess the role of PDE5 inhibition in control of
CCM. C57BL/6 mice were infected with T. cruzi, and
treated with SIL at the end of acute parasitemia. Mice
were assessed for cardiac pathology in the chronic
disease phase (150 days pi).
The cGMP/PKG signals the contraction and relaxa-
tion of vascular smooth muscle cells and cardiac myo-
cytes, and PDE5 may contribute to stress, for example,
pressure overload, induced cardiac remodeling (18).
We, therefore, ﬁrst determined whether PKG/PDE5
imbalance contributes to disturbed LV systolic func-
tion and cardiac remodeling in chagasic disease. The
PKG activity was decreased by 2.1-fold and PDE5
expression was increased by >1.4-fold at the mRNA
level and by 110% at the protein level in the myocar-
dium of chagasic (vs. normal) mice (Figure 1A, a–d)
(all *p < 0.001ANOVA/Tukey). Transthoracic echocardi-
ography was performed to evaluate the LV function
in Tc-infected (SIL) mice). Our data showed that
stroke volume (SV), cardiac output, and ejection frac-
tion (EF) were decreased by 55%, 52%, and 42%,
respectively, in chronically infected/untreated mice
(Figure 1B, a–c) (all *p < 0.001K-W/Dunn). SIL treatment
resulted in normal levels of PKG activity and PDE5
expression in the myocardium of chagasic mice
(Figure 1A, a–d) (all #p < 0.001ANOVA/Tukey), and subse-
quently, LV systolic function (SV, cardiac output, EF)
was preserved in chagasic/SIL-treated mice, when
compared with that noted in infected/untreated mice
(Figures 1A and 1B, a–c) (all #p < 0.001K-W/Dunn).
SIL-treated mice also exhibited normal levels of
fractional shortening and LV posterior wall
thickness that were decreased by 62.3% and 40.5%,
respectively, in Tc-infected mice (Figure 1B, d–e) (all
*,#p < 0.001K-W/Dunn). The signiﬁcant improvement in
LV function anddimensions inTc-infected/SIL-treated
mice were also observed when median  QR1 values
were calculated (SV [ml]: 35.34  9.01, 15.63  3.32**,
35.25  7.95###; % fractional shortening 32.22  8.99,
13.28  6.55***, 40.34  13.32###; and LV posterior wall
thickness [mm] 0.97  0.48, 0.51  0.40*, 1.25 
0.44###; normal, Tc-infected, Tc-infected/SIL-treated,
respectively, *,#p < 0.5K-W/Dunn).
Histological and molecular analysis of the myocar-
dium showed the collagen deposits were increased by
FIGURE 1 SIL Controlled LV Dysfunction and Cardiac Remodeling in Chagasic Mice
C57BL/6 mice were infected with Trypanosoma cruzi (Tc), and treated with sildenaﬁl (SIL) for 3 weeks, beginning at day 45 post-infection (pi).
Peripheral blood and heart tissues were collected at 150 days pi. (A) Shown are the myocardial levels of cGMP-dependent protein kinase
activity (PKG) (a), PDE5 mRNA by real-time quantitative reverse-transcription polymerase chain reaction (RT-PCR) (b), and PDE5 protein level
by Western blotting (c). Densitometry units for PDE5 were normalized to GAPDH (B) transthoracic echocardiography was performed by using a
Vevo 2100 System. Shown are (a) stroke volume, (b) cardiac output, (c) ejection fraction, (d) fractional shortening, and (e) left ventricular (LV)
posterior wall thickness at diastole (LVPW). (C) Heart tissue sections were stained with Mason’s Trichrome (a–c, magniﬁcation 20), and scored
for ﬁbrosis (d) as described in Materials and Methods. (D) Quantitative RT-PCR analysis of mRNA levels for collagen isoforms COLI and COLIII
(a and b) and SERCA2 (c) in heart tissue of chronically infected (SIL) mice. In all ﬁgures, data are plotted as mean  SEM (n ¼ 6 to 8 mice per
group). Signiﬁcance is shown with an asterisk (Tc-infected vs. matched control) or hash mark (infected/untreated vs. infected/SIL-treated), and
presented as *,#p < 0.05, **,##p < 0.01, ***,###p < 0.001. Mason’s T ¼ Mason’s Trichrome; Nor ¼ normal.
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 4 , 2 0 1 6 Wen et al.
J U N E 2 0 1 6 : 2 3 5 – 5 0 Sildenaﬁl Efﬁcacy in Chagas Disease
241
Wen et al. J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 4 , 2 0 1 6
Sildenaﬁl Efﬁcacy in Chagas Disease J U N E 2 0 1 6 : 2 3 5 – 5 0
242>12-fold (Figure 1C, b and d) (score 4.0  0.392
vs. 0.3  0.04, *p < 0.001ANOVA/Tukey) and associated
with 117% to 175% increase in collagen (COLI and
COLIII) expression (Figure 1D, a and b) (*p <
0.001ANOVA/Tukey) in chronically infected (vs. normal)
mice. The SERCA2mRNA level was decreased by 131%
in the myocardium of chagasic mice (Figure 1D, c) (*p <
0.001ANOVA/Tukey). SIL treatment resulted in >90%
control of Tc-induced collagen deposits and normali-
zation of the expression levels of collagen (COLI and
COLIII) and SERCA2 mRNAs in the chagasic myocar-
dium (Figures 1C and 1D) (#p < 0.001ANOVA/Tukey). These
data suggested that short-term treatment with SIL
maintained the PDE5–PKG balance and provided car-
dioprotective effects through reversal (or inhibition)
of adverse cardiac remodeling in chagasic mice.
Myocardial inﬂammatory response is important for
control of acute infection, but its chronic persistence
can contribute to cardiac tissue injury (27). PDE5 in-
hibitors may exert an anti-inﬂammatory effect by
raising cGMP levels and thereby prevent cellular
injuries in the heart. Histological studies showed
extensive, diffused inﬂammatory inﬁltrate in the
myocardium of chronically infected (vs. normal) mice
(histological score 4.0  0.39 vs. 0.3  0.036,
*p < 0.01ANOVA/Tukey) (Figure 2A, a and b). Further,
chronically infected mice exhibited a high degree of
myocardial degeneration with enlarged myocytes. In
comparison, minimal tissue inﬂammatory inﬁltrate
(histological score 0.91  0.12, #p < 0.01ANOVA/Tukey)
(Figure 2A, c) was detectable in chronically infected/
SIL-treated mice. The myocardial and plasma levels
of LDH (cellular injury marker) were increased by
5-fold and 55%, respectively, in infected/untreated (vs.
normal) mice (Figure 2B, a and b) (all *p < 0.001ANOVA/
Tukey) but were maintained at normal levels in the SIL-
treated/infected mice (Figure 2B, a and b) (all
#p < 0.001ANOVA/Tukey). The control of chronic inﬂam-
matory inﬁltrate and myocardial injury was observed
despite the ﬁnding that tissue parasite burden was >2-
fold higher in infected/SIL-treated mice, compared
with that noted in infected/untreated mice (Figure 2C)
(#p < 0.001ANOVA/Tukey). These data suggested that SIL
treatment was effective in controlling myocardial
persistence of inﬂammatory inﬁltrate and tissue injury
during chronic Chagas disease.
Mitochondrial activity of electron transport chain
complexes is decreased in chagasic myocardium (28).
To determine whether PDE5 contributes to mitochon-
drial dysfunction, we ﬁrst performed quantitative
evaluation of the mitochondrial DNA (mtDNA)-
encoded gene expression in chagasic mice (SIL).
These data showed a coordinated decline (27% to 58%)
in the expression of mtDNA-encoded genes thatare essential for the assembly of functional complex 1
(ND1 and ND4), complex III (CYTB), complex IV
(COXIII), and complex V (ATP6) in cardiac biopsies of
chagasic mice, when compared with that noted in
normalmice (Figure 3A, a–e) (all *p<0.001ANOVA/Tukey).
In infected mice given SIL treatment, the ND1
mRNA level was preserved to normal level, and
the expression of CYTB and ATP6 was improved by
49% to 50% in comparison to that noted in chagasic/
untreated mice (Figure 3A, a–e) (all #p < 0.05 to
0.001ANOVA/Tukey).
To determine whether SIL beneﬁts in normalizing
mtDNA gene expression inﬂuences the mitochondrial
function, we assessed the oxygen consumption rate
as a measure of mitochondrial oxidative metabolism
in chagasic mice ( SIL). The ADP-coupled state 3
respiration (indicates proton gradient for ATP syn-
thesis), driven with electron input from complex
I (pyruvate þ glutamate þ malate) and complex II
(succinate þ rotenone) substrates, was decreased by
42% to 58% in isolated cardiac mitochondria of
chagasic (vs. normal) mice (Figure 3B, a and b)
(*p < 0.001K-W/Dunn). Respiratory control ratio (RCR)
(state 3/state 4, indicates mitochondrial integrity)
was not disturbed in complex I respiring mitochon-
dria from any of the Tc-infected mice, whereas com-
plex II–driven RCR was decreased by 40% in cardiac
mitochondria of Tc-infected mice (Figure 3B, c)
(*p < 0.001K-W/Dunn). SIL treatment arrested the loss
in complex I–driven coupled respiration (Figure 3B, a)
(median  QR1: 41.37  10.82, 15.29  4.84***, 47.22 
32.98### n mol/min/mg mitochondrial protein,
normal, Tc-infected, Tc-infected/SIL-treated, respec-
tively, p < 0.001K-W/Dunn), but was not effective in
improving the loss in complex II–driven coupled
respiration and RCR in cardiac mitochondria of cha-
gasic mice (Figure 3B, b and c). These data suggested
that disease-associated compromise in mitochondrial
biogenesis and function were controlled, at least
partially, by SIL treatment of chagasic mice.
Because the loss in complex II–driven coupled
respiration was not controlled in chagasic mice with
SIL treatment, we expected that electron leakage
from the respiratory chain would result in increased
superoxide formation and oxidative stress in the
infected myocardium. Indeed, myocardial staining
with MitoSOX Red (detects mitochondrial ROS) was
increased in chagasic (vs. normal) mice (Figure 4A,
a and b). ROS action on polyunsaturated fatty acids
results in the formation of highly reactive LPOs; and
ROS-dependent direct oxidation of amino acids pro-
duces protein-derived aldehydes and ketones that
are collectively termed as carbonyls (29). The
myocardial and plasma levels of LPO and myocardial
FIGURE 2 Effects of SIL on Myocardial Inﬂammation and Parasite Burden in Chagasic Mice
C57BL/6 mice were infected and treated with SIL as described in the text. Shown are (A) hematoxylin and eosin staining (blue ¼ nuclear, pink ¼
muscle/cytoplasm/keratin) of heart tissue sections at 150 days pi (magniﬁcation 20). (B) The lactate dehydrogenase (LDH) activity in tissue
homogenates (a) and plasma (b) was measured by spectrophotometry. (C) Myocardial parasite burden was determined by real-time quanti-
tative PCR ampliﬁcation of Tc18SrDNA sequence. Results were normalized to murine GAPDH DNA and presented as fold change in TcDNA levels
in chronically infected mice (SIL). Abbreviations as in Figure 1.
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243carbonyl contents were increased by 2- to 3.5-fold in
chronically infected/untreated (vs. normal) mice
(Figure 4B, a–c) (all *p < 0.001ANOVA/Tukey). SIL
treatment abolished the myocardial increase in
mitochondrial ROS, LPO, and carbonyl contents, as
well as plasma LPO content, in chagasic mice
(Figures 4A and 4B) (all #p < 0.001ANOVA/Tukey). These
results, along with those presented in Figure 3, sug-
gested that SIL treatment arrested the chronic
oxidative adducts in chagasic myocardium, and
these beneﬁts were delivered by a mechanismindependent of control of complex II–driven loss in
coupled respiration.
SIL may have protective effects against oxidative
stress by supporting an antioxidant system (30). Our
data showed a 55% to 90% decline in GSK3b
and MnSOD mRNA levels (Figure 5A, a and b)
(p < 0.001K-W/Dunn and p < 0.001ANOVA/Tukey for panels
a and b, respectively) and 68% decline in MnSOD
activity (Figure 5B) (*p < 0.001ANOVA/Tukey) in the
myocardium of chagasic (vs. normal) mice. The
myocardial and plasma levels of total antioxidant
FIGURE 3 SIL Improved mtDNA-Encoded Gene Expression and Mitochondrial Respiration in Chagasic Mice
Mice were infected with T. cruzi and treated with SIL as described in the text. (A) Shown in a–e are the relative changes in gene expression for
the mitochondrial DNA (mtDNA)-encoded genes ND1, ND4, CYTB, COXIII, and ATP6, determined by real-time quantitative RT-PCR. Results were
normalized to GAPDH mRNA, and presented as fold change in mRNA levels in chronically infected mice (SIL) as compared with that noted in
normal control mice. (B) Cardiac mitochondria were isolated by differential centrifugation. Electron ﬂow in freshly isolated mitochondria was
supported with complex I (glutamate/pyruvate/malate, a) and complex II (succinate þ rotenone, b) substrates and the ADP-stimulated
state 3 respiration (i.e., oxygen consumption) was measured. Respiratory control ratio (RCR) (c) was calculated as the ratios between complex
II–supported state 3 and state 4 rates. Abbreviations as in Figure 1.
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244capacity, determined as trolox units, was decreased
by 74% and 45%, respectively, in chagasic mice
(Figure 5C, a and b) (all *p < 0.001ANOVA/Tukey). When
chagasic mice were treated with SIL, the myocardial
antioxidant expression (GSK3b and MnSOD mRNAs)
and MnSOD activity were only decreased by 20% and
10%, respectively, compared with that noted in
normal mice (Figures 5A and 5B) (all #p < 0.001ANOVA/
Tukey or K-W/Dunn). The signiﬁcant improvement in
GSK3b mRNA level by SIL treatment was also
observed when the median  QR1 value was calcu-
lated (fold change 1.03  1.15, 0.10  0.17***, and 0.60
 0.12### for normal, Tc-infected, and Tc-infected/
SIL-treated, respectively, *,#p < 0.001K-W/Dunn). Sub-
sequently, SIL-treated chagasic mice exhibited
normal levels of systemic and myocardial overall
antioxidant capacity (Figure 5C) (all #p < 0.001ANOVA/
Tukey). These data suggested that SIL treatmentenhanced the antioxidant capacity and allowed an
oxidant/antioxidant balance in chagasic mice.
To conﬁrm that SIL beneﬁts were indeed delivered
via regulating the antioxidant/oxidant balance, we
used an in vitro system. Cardiac myocytes were
infected with T. cruzi for 24 h, stained with intracel-
lular probes, and then analyzed by ﬂuorescence mi-
croscopy (Figure 6A). In response to T. cruzi infection,
ﬂuorescence of BCECF (detects normal pH) was
decreased, whereas ﬂuorescence of Fluo-4 (indicates
Ca2þ overload), DCF (detects intracellular H2O2), and
DHE (detects intracellular O2) were increased in
infected cardiac myocytes (Figure 6A, compare panels
b, e, h, and k with a, d, g, and j). SIL treatment restored
the normal intracellular pH, and partially decreased
the Tc-induced increase in intracellular Ca2þ ﬂux, and
ROS generation in cardiac myocytes (Figure 6A,
compare panels c, f, i, and l with b, e, h, and k). A
FIGURE 4 Oxidative Adducts in Chagasic Myocardium (SIL)
Mice were infected with T. cruzi and treated with SIL as described in the text. (A) Frozen heart tissue sections were incubated with MitoSOX Red
(detects mitochondrial reactive oxygen species, ﬂuoresces red) and imaged by ﬂuorescence microscopy (magniﬁcation 20). (B) Bar graphs
show myocardial (a) and plasma (b) levels of lipid hydroperoxides (LPO) in chronically infected (SIL) and control mice. (c) Myocardial protein
carbonyls by an enzyme-linked immunosorbent assay. Abbreviations as in Figure 1.
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245quantitative evaluation of oxidative stress by Amplex
red assay showed 7-fold and 3-fold increases in H2O2
release from infected/untreated and infected/SIL-
treated cardiac myocytes, respectively, as compared
with that noted in normal controls (Figure 6B)
(all *#p < 0.001ANOVA/Tukey). The NADþ/NADH ratio
reﬂects the metabolic activity and is an important
component of redox state of cells. The NADþ/NADH
ratio (Figure 6C) and cell viability (Figure 6D) were
decreased by 60% and 38%, respectively, in Tc-
infected cardiac myocytes (all *p < 0.001ANOVA/Tukey),
and treatment with SIL restored the normal NADþ/
NADH ratio and levels of cell viability in infected cells
(Figures 6C and 6D) (all #p < 0.001ANOVA/Tukey). Finally,to check whether the beneﬁts of SIL in chronically Tc-
infected mice would link the recovery of Tc-induced
MnSOD decline, cardiac myocytes were transfected
with pBI.EGFP or pBI.EGFP-MnSOD. Microscopic
visualization of the total (Figure 6E, a) and GFPþ
(Figure 6E, b) cells showed the transfection efﬁciency
was w72%. The pBI.EGFP-MnSOD–transfected cells
exhibited a 60% decline in EGFP ﬂuorescence
in response to T. cruzi infection (Figure 6E, c)
(*p < 0.001ANOVA/Tukey), and EGFP-MnSOD ﬂuores-
cence was normalized to control levels in infected/
SIL-treated cardiac myocytes (Figure 6E, c)
(#p < 0.001ANOVA/Tukey). Together, these data sug-
gested that SIL beneﬁts in preserving the redox
FIGURE 5 Myocardial Antioxidant Status in Chagasic Mice (SIL)
(A) Bar graphs show the mRNA levels for GSK3B (a) and MnSOD (b) antioxidants, determined by quantitative RT-PCR. Data were normalized to
GAPDH mRNA. (B) MnSOD enzymatic activity in heart tissue homogenates of normal, chagasic, and chagasic/SIL-treated mice. (C) Shown are
myocardial (a) and plasma (b) levels of total antioxidant capacity in normal and infected (SIL) mice. Abbreviations as in Figure 1.
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246metabolic state and cellular health were delivered via
preserving the antioxidant status that otherwise was
compromised in response to T. cruzi infection.
DISCUSSION
In this study, we tested the hypothesis that the PDE5
inhibitor SIL would be beneﬁcial in controlling the
chronic CCM caused by T. cruzi infection. Our proposal
was on the basis of the literature that NO/cGMP
maintain cardiac homeostasis and inotropy via PKG1a
activation (31), and PDE5 (catabolizes cGMP) is up
regulated in hypertrophied heart (16,32). Mice infec-
ted with T. cruzi controlled the acute parasitemia
within 45 days pi, but developed symptomatic CCC at
>120 days pi (33). We used this therapeutic window of
indeterminate phase for short-term treatment with
SIL for 21 days, beginning day 45 pi. Our data showed a
powerful protective effect of SIL against cardiac col-
lagenosis and LV dysfunction in chagasic heart. The
beneﬁcial effects of SIL were not delivered via its
direct effect on parasite persistence that is suggested
to be the major cause for the development of chronic
cardiomyopathy (reviewed in [34,35]). Instead, SIL
inhibition of PDE5 prevented the loss in PKG1a activ-
ity, enhanced the overall antioxidant response and
ROS scavenging capacity, and controlled the persis-
tence of oxidative adducts and inﬂammatory inﬁltrate
in chronic CCM. SIL treatment also controlled, at leastpartially, the ADP-coupled oxidative metabolism in
chagasic myocardium. To the best of our knowledge,
this is the ﬁrst study demonstrating that SIL arrests the
loss in antioxidant capacity and mitochondrial func-
tion and prevents the oxidative/inﬂammatory adducts
that precipitate cardiomyocytes death and cardiac
remodeling in CCM. We surmise that currently avail-
able PDE5 targeting drugs would potentially be useful
for long-term health care of CCM patients.
The role of cGMP/PKG pathway and the therapeutic
effect of PDE5 inhibitors have been well characterized
in the pulmonary vasculature (36). The observation of
increased expression of PDE5 in heart biopsies (or
isolated primary cardiomyocytes) from patients
exhibiting hypertrophy (37) and dilated or ischemic
cardiomyopathy (38) fueled the research efforts
investigating the beneﬁts of PDE5 inhibitor in heart
disease. Indeed, several studies in experimental
models have demonstrated the beneﬁcial effects of
PDEF5 inhibitor in treating the acute ischemia/
reperfusion-induced myocardial injury (21), pressure
overload–induced cardiac hypertrophy (39), and heart
failure of other etiologies. Recent studies have sug-
gested the beneﬁts of PDE5 inhibition in preserving
the heart are delivered by decreasing the mitochon-
drial oxidative stress and increasing the antioxidant
status in mice and cardiomyocytes (17–20).
C57BL/6 mice exhibit peak parasitemia during
acute phase (14 to 35 days pi) (33). Myocardial
FIGURE 6 SIL Preserves the Oxidant/Antioxidant Balance in Cardiomyocytes Infected With T. cruzi
(A) Cardiac myocytes were infected with T. cruzi (cell/parasite ratio 1:5), and incubated for 24 h in the presence or absence of 10 nmol/l sildenaﬁl. Cells were loaded with BCECF
(ﬂuoresces at normal pH, a–c), Fluo-4 (ﬂuorescence shows intracellular Caþ2 level, d–f), H2DCFDA (oxidized by intracellular reactive oxygen species [ROS] to ﬂuorescent
dichlorodihydroﬂuorescein [DCF], g–i), or DHE (oxidized by intracellular ROS to ﬂuorescent ethidium, j–l). Shown are the representative images (magniﬁcation 40), captured by
ﬂuorescencemicroscopy. (B–D)Cardiacmyocyteswere infectedwithTc (SIL).Bargraphsshow (B)ROSreleasebyanAmplex redassay, (C)NADþ/NADHratio,and (D) cell viability
byMTT assay. (E)Cardiacmyocyteswere transfectedwith pBI.EGFP-MnSODexpressionplasmid, infectedwithT. cruzi, and incubated in thepresenceor absence of sildenaﬁl for 24
h. Bar graph shows MnSOD expression by EGFP-dependent ﬂuorimetry. OD¼ optical density; RFU ¼ relative ﬂuorescence units; other abbreviations as in Figure 1.
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247remodeling, that is, increase in collagen isoforms and
decline in SERCA2 mRNA (Figure 1D), were prominent
during the chronic phase that begun by w120 days pi
(33). Chronically infected chagasic mice developed LV
systolic dysfunction evidenced by 42% to 55% decline
in SV, cardiac output, and EF as is noted in chroni-
cally infected chagasic patients (Figure 1). Histological
and molecular studies showed the infected mice
showed cardiac collagenosis, extensive inﬁltration ofinﬂammatory inﬁltrate and oxidative adducts in the
heart that are hallmarks of CCM (Figure 1). Little is
known about why echocardiographic parameters are
altered in CCM; however, treatment with SIL pro-
vided enormous cardioprotective effects via preser-
vation of LV systolic function in chagasic mice. Our
ﬁndings of reduced LV wall thickness and cardiac
ﬁbrosis in SIL-treated mice may be indicative of a
long-term, sustained improvement against CCM.
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248We surmise that mice mimic the human development
of clinical disease, and provided an excellent model
system to demonstrate the therapeutic efﬁcacy of SIL
against CCM.
We and others have previously shown that T. cruzi
invasion results in mitochondrial respiratory chain
inefﬁciency and increased release of electrons to O2
and O2 production in cardiomyocytes (40) and
chagasic hearts (24,41,42). PGC1-a is the master
regulator of mitochondrial biogenesis (43,44), and
indeed the mtDNA-encoded gene expression was
normalized in the myocardium of chagasic mice by
SIL treatment; and subsequently, SIL was effective in
improving the complex I–driven electron gradient
and ADP-coupled respiration (Figure 3). It is of note
that mtDNA does not encode any of the subunits
required for the assembly of complex II (45), and SIL
had no beneﬁcial impact in preserving the complex II–
driven mitochondrial oxygen consumption in the
chagasic heart (Figure 3). This observation suggests
that mechanism(s) other than the compromise in
mtDNA-encoded gene expression contribute to com-
plex II–driven respiratory inefﬁciency in Chagas dis-
ease, to be delineated in future studies.
Despite the continuation of the loss in CII complex
driven respiration, SIL treatment was effective in
attenuating the Tc-induced mitochondrial ROS,
myocardial oxidative adducts (protein carbonyls and
LPO), and cell death (Figure 4). Chronic oxidative
stress is shown to correlate with increased expression
of PDE5 in myocytes during chronic heart failure (46),
though the physiological or mechanistic relevance of
PDE5 in aggravating oxidative stress is unknown.
Likewise, it is not known whether control of oxidative
damage by PDE5 inhibitor is causatively related with
cGMP/PKG activation. Yet, increase in cGMP can
inhibit NADPH oxidase expression/activity, thereby
reducing O2 production (47). Our in vitro and in vivo
studies suggested that PDE5 was at the nexus of
compromised antioxidant response, and SIL treatment
enhanced the ROS scavenging capacity by activation of
MnSOD expression and activity (Figures 5 and 6); and
thereby the underlying cause for oxidant/antioxidant
imbalance in response to T. cruzi infection. The po-
tential advantage of a therapeutic approach on the
basis of inhibition of PDE5 appears to be the host’s
ability to avoid risks associated with excessive O2
and NO that lead to overproduction of a highly stable,
peroxynitrite-free radical. Further studies will be
required to elucidate whether PDE5 suppresses the
antioxidant capacity via targeting the PGC-1-a/NRF2
pathway of antioxidant response in the heart.
A recent study showed that T. cruzi signals both
TGF-b–dependent and -independent ﬁbrotic pathwaysin cardiacmyocytes (9), providing evidence for the role
of the parasite in eliciting cardiac hypertrophy. The
current published reports also accept that parasite
persistence is the main cause for chronic cardiac
inﬂammation, cardiomyocytes’ injury and death, and
myoﬁbroblasts’ involvement in cardiac remodeling in
Chagas disease (reviewed in [48]). However, in this
study, SIL-treated/infected mice exhibited an increase
in tissue parasite burden when compared with that
noted in untreated/infected mice, and still controlled
the collagenosis, oxidative and inﬂammatory stress,
and LV dysfunction. These data suggested that para-
site persistence is not the sole cause for continuance of
injurious processes in the heart. Indeed, intracellular
proteins (e.g., myosin) that are exposed to immune
system due to cardiomyocyte injuries are shown to
sustain chronic activation of T-cell responses in Cha-
gas disease (49–51). We have found that post-
translational oxidative modiﬁcations of cardiac pro-
teins generated neoantigens that were recognized by
serum antibodies in chagasic patients, and this
response paralleled with the pathological events dur-
ing Chagas disease development (52). Treatment of
infected rodents with chemical antioxidant provided a
signiﬁcant control of cardiac remodeling and antibody
cytotoxicity directed against cardiac proteins (12).
Thus, we surmise that besides parasite persistence,
host factors (e.g., oxidative stress, oxidized antigens)
play an important role in chronic inﬂammation in
Chagas disease, and cardioprotective effects of SIL
were delivered via preserving the oxidant/antioxidant
balance and limiting the nonspeciﬁc immune activa-
tion in the chagasic host.
A novel observation in this study was that T. cruzi
infection decreased the expression of SERCA2. SERCA2
is a Ca2þATPase that transfers Ca2þ from the cytosol of
the cell to the lumen of the sarcoplasmic reticulum at
the expense of ATP hydrolysis during muscle relaxa-
tion (53). Several studies have suggested the SERCA2/
endoplasmic reticulum (ER) stress dysregulates the
intracellular Ca2þ cycling and contributes to the risk of
future heart failure events (54). It is shown that in-
duction of ER stress in human heart failure was
signiﬁcantly correlated with increased myocardial
PDE5 expression, and SIL treatment reduced the
ER stress and corresponding cell apoptosis in
isoprenaline-induced heart failure; studies in cultured
cardiomyocytes showed similar results (55). Our
ﬁnding of improved SERCA2 expression in SIL-treated
chagasic mice and Caþ2 handling in Tc-infected/SIL-
treated cardiomyocytes provide further evidence that
PDE5 inhibition in heart failure might contribute to
attenuation of ER stress through increased SERCA
activity and restoration of intracellular Ca2þbalance.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Trypanosoma
cruzi protozoan parasite remain the most common cause of
nonischemic cardiomyopathy (called Chagas disease) in Latin
America. A recent prospective, multicenter randomized study
involving >2,800 patients with Chagas cardiomyopathy who
received benznidazole (antiparasite drug) or placebo concluded
that treatment with antiparasite drug provided no signiﬁcant
beneﬁt in reducing the cardiac clinical deterioration through
5 years of follow-up. There is no speciﬁc treatment available to
control the progressive cardiomyopathy in chagasic patients.
Current literature suggests that nitric oxide and cGMP maintain
cardiac homeostasis and inotropy via cGMP-dependent protein
kinase (PKG1a) activation, and PDE5 (catabolizes cGMP) is
upregulated in hypertrophy conditions. Thus, we examined the
therapeutic efﬁcacy of PDE5 inhibitor (sildenaﬁl) in a murine
model of Chagas disease. Sildenaﬁl treatment during a thera-
peutic window (i.e., after control of acute parasitemia but before
development of cardiomyopathy) had a powerful cardioprotec-
tive effect against cardiac collagenosis and left ventricular
dysfunction in chagasic disease.
TRANSLATIONAL OUTLOOK: Currently available PDE5 tar-
geting drugs would potentially be useful for long-term health
care of chagasic cardiomyopathy patients.
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249Although several studies have shown increased
expression of PDE5 in diseased heart and the beneﬁts
of PDE5 inhibitors in improving heart failure with
lower ejection fraction, several controversies remain.
Some investigators have noted no increase in hyper-
trophy upon deletion of cGMP/PKG in cardiomyocytes
(56), whereas others have suggested that PDE5
expression in normal heart and in cardiac biopsies of
mammalian models of heart failure as well as in
humans with heart failure occur at a very low level
(57), and the effects of SIL on cGMP hydrolysis in
experimental models of ischemia/perfusion were
likely through inhibition of PDE1 (along with PDE5)
(58). A recently concluded randomized clinical trial of
heart failure patients with preserved ejection fraction
(>50%) showed no signiﬁcant beneﬁcial effect of SIL
in improving the exercise capacity or clinical status.
Clearly, large randomized trials with careful docu-
mentation and analysis of effects of PDE5 inhibitors
on micro and macro parameters of heart pathology
and physiology will be required before the use of
PDE5 inhibitors for management of heart disease can
be clinically implemented.
CONCLUSIONS
In summary, our ﬁndings provide the ﬁrst evidence
that SIL has a powerful cardioprotective effect against
cardiac collagenosis and LV dysfunction in chagasic
disease. SIL inhibition of PDE5 enhanced the overall
antioxidant response and ROS scavenging capacity,
and controlled the chronic oxidative and inﬂamma-
tory stress in chagasic heart. SIL treatment also
restored, at least partially, the mitochondrial oxida-
tive metabolism in chagasic myocardium. These re-
sults provide us impetus to test the potential efﬁcacy
of available PDE5 targeting drugs in other animal
models of Chagas disease, and subsequently, in cha-
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